Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
36
SNN Quote, Financials, Valuation and Earnings
Last price:
$32.81
Seasonality move
:
6.32%
Day range:
$32.76 - $33.19
52-week range:
$23.69 - $38.79
Dividend yield:
2.32%
P/E ratio:
29.48x
P/S ratio:
2.42x
P/B ratio:
3.46x
Volume:
400.5K
Avg. volume:
494.5K
1-year change:
33.48%
Market cap:
$14B
Revenue:
$5.8B
EPS (TTM):
$1.13
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNN
Smith & Nephew plc
|
$1.7B | -- | -- | -- | $36.63 |
|
AUTL
Autolus Therapeutics Plc
|
$24.3M | -$0.40 | 84624.25% | -288.08% | $9.63 |
|
AZN
AstraZeneca PLC
|
$15.4B | $1.09 | 4.59% | 128.14% | $98.96 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.1M | -$0.94 | 92.62% | -25.75% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNN
Smith & Nephew plc
|
$32.81 | $36.63 | $14B | 29.48x | $0.30 | 2.32% | 2.42x |
|
AUTL
Autolus Therapeutics Plc
|
$1.99 | $9.63 | $529.6M | -- | $0.00 | 0% | 10.33x |
|
AZN
AstraZeneca PLC
|
$91.93 | $98.96 | $285B | 30.53x | $0.52 | 1.7% | 4.94x |
|
BCYC
Bicycle Therapeutics Plc
|
$7.08 | $21.50 | $491.1M | -- | $0.00 | 0% | 17.31x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.27 | $17.94 | $1.9M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$3.60 | $104.00 | $15M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNN
Smith & Nephew plc
|
36.96% | 0.278 | -- | 1.40x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
AZN
AstraZeneca PLC
|
41.56% | 0.018 | 13.71% | 0.66x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 1.504 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNN
Smith & Nephew plc
|
-- | -- | 5.7% | 9.2% | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Smith & Nephew plc vs. Competitors
-
Which has Higher Returns SNN or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Smith & Nephew plc's net margin of -373.3%. Smith & Nephew plc's return on equity of 9.2% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About SNN or AUTL?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 11.64%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.63 which suggests that it could grow by 384.09%. Given that Autolus Therapeutics Plc has higher upside potential than Smith & Nephew plc, analysts believe Autolus Therapeutics Plc is more attractive than Smith & Nephew plc.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is SNN or AUTL More Risky?
Smith & Nephew plc has a beta of 0.623, which suggesting that the stock is 37.671% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.012, suggesting its more volatile than the S&P 500 by 101.185%.
-
Which is a Better Dividend Stock SNN or AUTL?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.32%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or AUTL?
Smith & Nephew plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Smith & Nephew plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.48x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.42x versus 10.33x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.42x 29.48x -- -- AUTLAutolus Therapeutics Plc10.33x -- $21.1M -$78.6M
-
Which has Higher Returns SNN or AZN?
AstraZeneca PLC has a net margin of -- compared to Smith & Nephew plc's net margin of 16.69%. Smith & Nephew plc's return on equity of 9.2% beat AstraZeneca PLC's return on equity of 22.01%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B AZNAstraZeneca PLC73.89% $0.81 $78.6B -
What do Analysts Say About SNN or AZN?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 11.64%. On the other hand AstraZeneca PLC has an analysts' consensus of $98.96 which suggests that it could grow by 7.64%. Given that Smith & Nephew plc has higher upside potential than AstraZeneca PLC, analysts believe Smith & Nephew plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 AZNAstraZeneca PLC8 1 0 -
Is SNN or AZN More Risky?
Smith & Nephew plc has a beta of 0.623, which suggesting that the stock is 37.671% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.335, suggesting its less volatile than the S&P 500 by 66.49%.
-
Which is a Better Dividend Stock SNN or AZN?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.32%. AstraZeneca PLC offers a yield of 1.7% to investors and pays a quarterly dividend of $0.52 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. AstraZeneca PLC pays out 66.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or AZN?
Smith & Nephew plc quarterly revenues are --, which are smaller than AstraZeneca PLC quarterly revenues of $15.1B. Smith & Nephew plc's net income of -- is lower than AstraZeneca PLC's net income of $2.5B. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.48x while AstraZeneca PLC's PE ratio is 30.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.42x versus 4.94x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.42x 29.48x -- -- AZNAstraZeneca PLC4.94x 30.53x $15.1B $2.5B
-
Which has Higher Returns SNN or BCYC?
Bicycle Therapeutics Plc has a net margin of -- compared to Smith & Nephew plc's net margin of -503.67%. Smith & Nephew plc's return on equity of 9.2% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About SNN or BCYC?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 11.64%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 203.67%. Given that Bicycle Therapeutics Plc has higher upside potential than Smith & Nephew plc, analysts believe Bicycle Therapeutics Plc is more attractive than Smith & Nephew plc.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is SNN or BCYC More Risky?
Smith & Nephew plc has a beta of 0.623, which suggesting that the stock is 37.671% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.42%.
-
Which is a Better Dividend Stock SNN or BCYC?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.32%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or BCYC?
Smith & Nephew plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $11.7M. Smith & Nephew plc's net income of -- is lower than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.48x while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.42x versus 17.31x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.42x 29.48x -- -- BCYCBicycle Therapeutics Plc17.31x -- $11.7M -$58.7M
-
Which has Higher Returns SNN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Smith & Nephew plc's net margin of --. Smith & Nephew plc's return on equity of 9.2% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About SNN or BDRX?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 11.64%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 7734.86%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Smith & Nephew plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Smith & Nephew plc.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is SNN or BDRX More Risky?
Smith & Nephew plc has a beta of 0.623, which suggesting that the stock is 37.671% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock SNN or BDRX?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.32%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or BDRX?
Smith & Nephew plc quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Smith & Nephew plc's net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.48x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.42x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.42x 29.48x -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns SNN or NCNA?
NuCana Plc has a net margin of -- compared to Smith & Nephew plc's net margin of --. Smith & Nephew plc's return on equity of 9.2% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About SNN or NCNA?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 11.64%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 577677.78%. Given that NuCana Plc has higher upside potential than Smith & Nephew plc, analysts believe NuCana Plc is more attractive than Smith & Nephew plc.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 NCNANuCana Plc0 1 0 -
Is SNN or NCNA More Risky?
Smith & Nephew plc has a beta of 0.623, which suggesting that the stock is 37.671% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock SNN or NCNA?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.32%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or NCNA?
Smith & Nephew plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Smith & Nephew plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.48x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.42x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.42x 29.48x -- -- NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
